Venetoclax in patients with previously treated chronic lymphocytic leukemia
- Author(s)
- Roberts, AW; Stilgenbauer, S; Seymour, JF; Huang, DC;
- Details
- Publication Year 2017-01-18,Volume 23,Issue #16,Page 4527-4533
- Journal Title
- Clinical Cancer Research
- Publication Type
- Journal Article
- Abstract
- Venetoclax is the first BCL2 inhibitor to enter routine clinical practice. It is an orally bioavailable small molecule that binds BCL2 very specifically. Acting as a pharmacological mimic of the proteins that initiate apoptosis (a so-called BH3-mimetic), venetoclax rapidly induces apoptosis in chronic lymphocytic leukemia (CLL) cells which express high levels of BCL2 and rely on it to maintain their survival. As a single agent, daily venetoclax treatment induced durable responses in 79% of patients with relapsed or refractory CLL or small lymphocytic lymphoma in a Phase 1 study, including complete remissions in 20% of patients. Its use was approved by the FDA in April 2016 for patients with previously treated del(17p) CLL on the basis of a single arm Phase 2 trial demonstrating a 79% response rate and an estimated 1 year progression-free survival of 72% with 400mg/day continuous therapy. This review focuses on venetoclax, its mechanism-of-action, pharmacology and clinical trial data, and seeks to place it in the context of rapid advances in therapy for patients with relapsed CLL, especially those with del(17p) CLL.
- Publisher
- AACR
- Research Division(s)
- Cancer And Haematology
- PubMed ID
- 28100580
- Publisher's Version
- https://doi.org/10.1158/1078-0432.CCR-16-0955
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2017-04-06 09:27:26
Last Modified: 2020-04-07 02:16:29